IL1B and rheumatoid arthritis: As a result, certain patients are refractory to current cytokine-based therapies, and in spite of the pivotal role of IL-1β in maintaining synovitis and inducing bone erosion, IL-1 blockade shows limited efficacy in improving clinical symptoms of RA patients [15].